They’re being hailed as the “wonder drug” of the century, and millions are jumping on GLP-1s so desperately that some are buying shadowy gray-market shots. But as long-term safety questions and ugly
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Sept 22 (Reuters) - Goldman Sachs has appointed Simon Lyons as co-head of UK investment…
Sep 23 (Stats Perform) - Results from the MLB games on Tuesday (home team in…
By Ross Kerber Sept 22 (Reuters) - Microsoft will consider shareholder proposals at its annual…
Griffin Conine plated the go-ahead run in the 12th inning for the visiting Miami Marlins,…
Sept 23 (Reuters) - ASX's clearing and settlement facilities continue to fail to meet the…
By Solomon Cefai SINGAPORE, Sept 23 (Reuters) - Copper drifted down on Wednesday, weighed by…